Get the Stockscreener App
3.51
3.24%
0.11
Pre-market:
3.50
-0.010
-0.28%
Sonoma Pharmaceuticals Inc stock is traded at $3.51, with a volume of 966.29K.
It is up +3.24% in the last 24 hours and up +38.19% over the past month.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
See More
Previous Close:
$3.40
Open:
$3.23
24h Volume:
966.29K
Relative Volume:
0.66
Market Cap:
$5.67M
Revenue:
$12.31M
Net Income/Loss:
$-5.08M
P/E Ratio:
-3.734
EPS:
-0.94
Net Cash Flow:
$-5.20M
1W Performance:
+64.79%
1M Performance:
+38.19%
6M Performance:
+10.73%
1Y Performance:
+25.36%
1-Day Range:
$3.05
$3.60
1-Week Range:
$1.90
$4.46
52-Week Range:
$1.90
$9.374
Sonoma Pharmaceuticals Inc Stock (SNOA) Company Profile
Name
Sonoma Pharmaceuticals Inc
Sector
Phone
800-759-9305
Address
5445 CONESTOGA COURT, SUITE 150, BOULDER, CA
Compare SNOA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNOA
Sonoma Pharmaceuticals Inc
|
3.51 | 5.67M | 12.31M | -5.08M | -5.20M | -0.94 |
|
ZTS
Zoetis Inc
|
161.68 | 72.40B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.93 | 47.12B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.19 | 46.08B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.48 | 18.88B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.25 | 13.96B | 612.78M | -86.37M | -62.91M | -0.87 |
Sonoma Pharmaceuticals Inc Stock (SNOA) Latest News
Scar Management Market Top PlayersNewmedical Technology - openPR
Why Fast-paced Mover Sonoma Pharmaceuticals (SNOA) Is a Great Choice for Value Investors - Yahoo Finance
SNOA's Wound Care Products Get Regulatory Clearance, LFMD's Q4 Revenue Soars, ATRA On Watch - RTTNews
Sonoma Pharmaceuticals expands into UK market By Investing.com - Investing.com Australia
Sonoma Pharmaceuticals expands into UK market - Investing.com India
Sonoma Pharmaceuticals Secures Extensive U.K. Regulatory Clearances of Key Wound Care and Dermatology Products by the Medicines & Healthcare Products Regulatory Agency (MHRA) - ACCESS Newswire
Why Checkpoint Therapeutics Shares Are Trading Higher By Around 66%; Here Are 20 Stocks Moving Premarket - Benzinga
Market Cool On Sonoma Pharmaceuticals, Inc.'s (NASDAQ:SNOA) Revenues Pushing Shares 25% Lower - Simply Wall St
SNOA stock touches 52-week low at $2 amid market challenges - Investing.com Australia
SNOA stock touches 52-week low at $2 amid market challenges By Investing.com - Investing.com South Africa
Sonoma Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Scar Treatment Market Projected To Witness Massive Growth, - openPR
Addex Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:ADXN - Benzinga
Virpax Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:VRPX - Benzinga
Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn(R) Disinfectant & Sanitizer has been Approved by the Australian TGA as Effective Against Candida auris and C-Diff - ACCESS Newswire
SNOA Stock Touches 52-Week Low at $2.29 Amid Market Challenges By Investing.com - Investing.com South Africa
SNOA Stock Touches 52-Week Low at $2.29 Amid Market Challenges - Investing.com
Sonoma Pharmaceuticals to Exhibit at 2025 American Academy of Dermatology Annual Meeting in Orlando - ACCESS Newswire
How Sonoma Pharmaceuticals Plans to Expand Its Dermatology Footprint at Major 2025 Industry Event - StockTitan
Investor Network: Sonoma Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Sonoma Pharmaceuticals secures new supply agreement - MSN
SNOA stock touches 52-week low at $2.44 amid market challenges - Investing.com Canada
Sonoma County earmarks opioid settlement money for treatment, education programs - MSN
More Musk-like 'Dexits' pose fresh threat to Delaware's corporation crown - Yahoo Finance
CNS Pharma (NASDAQ:CNSP) Stock Quotes, Forecast and News Summary - Benzinga
Head-To-Head Survey: Sonoma Pharmaceuticals (NASDAQ:SNOA) and BrainsWay (NASDAQ:BWAY) - Defense World
Redhill Biopharma (NASDAQ:RDHL) Stock Quotes, Forecast and News Summary - Benzinga
Head-To-Head Survey: Sonoma Pharmaceuticals (NASDAQ:SNOA) vs. Femasys (NASDAQ:FEMY) - Defense World
Keloid Treatment Market in 2022: Forecast to Reach $4.72 Bn by 2031. - openPR
Is Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Worth US$2.7 Based On Its Intrinsic Value? - Yahoo Finance
Sonoma Pharmaceuticals (SNOA) to Release Quarterly Earnings on Thursday - Defense World
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 - Marketscreener.com
Sonoma Pharmaceuticals Inc. (SNOA) reports earnings - Quartz
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2025 Financial Results - ACCESS Newswire
Earnings Alert: Sonoma Pharma Delivers Double-Digit Growth, Secures Major Distribution Deals - StockTitan
Sonoma Pharmaceuticals (NASDAQ:SNOA) Share Price Passes Above Two Hundred Day Moving Average – Here’s What Happened - Defense World
Sonoma Pharmaceuticals secures new supply agreement By Investing.com - Investing.com Canada
Dental Market Future Business Opportunities 2025-2032 | - openPR
Hypertrophic And Keloid Scar Treatment Global Market Expected To Ascend to $12.51 Billion By 2029 - WhaTech
Sonoma Pharmaceuticals (SNOA) Stock Surges Amid Industry Decline - GuruFocus.com
Sonoma Pharmaceuticals to Present at Danisavage Financial Strategies, and LD Micro Main Event XVII Investor Conferences - ACCESS Newswire
Sonoma Pharmaceuticals to Exhibit at Upcoming CPHI Conference in Frankfurt, Germany - ACCESS Newswire
Sonoma Pharmaceuticals Announces MicrocynAH for Animal Health Now Available Through Menards Home Improvement Stores - ACCESS Newswire
Sonoma Pharmaceuticals Announces Partnership with Daewoong Pharmaceutical for Distribution of Primocyn Skin Care in South Korea - ACCESS Newswire
Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections - ACCESS Newswire
Sonoma Pharmaceuticals Inc Stock (SNOA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.49%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):